These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Srinivasan S; Fu KP; Neu HC Antimicrob Agents Chemother; 1981 Feb; 19(2):302-5. PubMed ID: 6214989 [TBL] [Abstract][Full Text] [Related]
3. Effect of probenecid on the pharmacokinetics of moxalactam. DeSante KA; Israel KS; Brier GL; Wolny JD; Hatcher BL Antimicrob Agents Chemother; 1982 Jan; 21(1):58-61. PubMed ID: 6211135 [TBL] [Abstract][Full Text] [Related]
4. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Scheld WM; Spyker DA; Donowitz GR; Bolton WK; Sande MA Antimicrob Agents Chemother; 1981 Apr; 19(4):613-9. PubMed ID: 6454387 [TBL] [Abstract][Full Text] [Related]
5. Penetration of moxalactam and cefazolin into bone following simultaneous bolus or infusion. Polk R; Hume A; Kline BJ; Cardea J Clin Orthop Relat Res; 1983; (177):216-21. PubMed ID: 6222858 [TBL] [Abstract][Full Text] [Related]
6. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion. Polk RE; Kline BJ; Markowitz SM Antimicrob Agents Chemother; 1981 Nov; 20(5):576-9. PubMed ID: 6459759 [TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers. Standiford HC; Drusano GL; McNamee WB; Tatem B; Ryan PA; Schimpff SC Rev Infect Dis; 1982; 4 Suppl():S585-94. PubMed ID: 6296967 [TBL] [Abstract][Full Text] [Related]
8. Absorption, excretion, and clinical efficacy of moxalactam in pediatric patients. Fujii R Rev Infect Dis; 1982; 4 Suppl():S656-63. PubMed ID: 6218579 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of moxalactam in patients with normal and impaired renal function. Aronoff GR; Sloan RS; Luft FC J Infect Dis; 1982 Mar; 145(3):365-9. PubMed ID: 6460824 [TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of moxalactam in patients with malignant disease. Estey EH; Weaver SS; Ho DH; Bodey GP Antimicrob Agents Chemother; 1981 Apr; 19(4):639-44. PubMed ID: 6454389 [TBL] [Abstract][Full Text] [Related]
11. [Comparative pharmacokinetics of moxalactam and other cephalosporins]. Fourtillan JB; Brisson AM Sem Hop; 1983 Jun; 59(26):1968-71. PubMed ID: 6310788 [TBL] [Abstract][Full Text] [Related]
12. Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Singlas E; Boutron HF; Merdjan H; Brocard JF; Pocheville M; Fries D Clin Pharmacol Ther; 1983 Sep; 34(3):403-7. PubMed ID: 6224624 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of moxalactam in patients with renal insufficiency. Lam M; Manion CV; Czerwinski AW Antimicrob Agents Chemother; 1981 Mar; 19(3):461-4. PubMed ID: 6454383 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Bolton WK; Scheld WM; Spyker DA; Overby TL; Sande MA Antimicrob Agents Chemother; 1980 Dec; 18(6):933-8. PubMed ID: 6453555 [TBL] [Abstract][Full Text] [Related]
20. A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic. Neu HC Ther Drug Monit; 1981; 3(2):121-8. PubMed ID: 6455787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]